Pravastatin/fenofibrate (Pravafenix) for the indication ‘dyslipidaemia with high-concentration triglycerides’

The use of pravastatin/fenofibrate to treat adult patients with an increased risk of coronorary heart disease and who suffer from mixed dyslipidaemia characterised by high concentrations of triglycerides, low concentrations of HDL-cholesterol and sufficiently managed concentrations of LDL-cholesterol during treatment with pravastatin 40 mg monotherapy has a lower therapeutic value than treatment with pravastatin 40 mg or simvastatin 20 mg.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.